pimecrolimus topical / Generic mfg. - LARVOL DELTA

Vulvar Malignancy Risk in Lichen Sclerosus: Differential Impact of Topical Therapies (AAD 2026) - "High-potency topical steroids, such as clobetasol, are first-line therapy, while topical calcineurin inhibitors (TCIs), including tacrolimus and pimecrolimus, are second-line [3]. These findings corroborate the elevated vulvar malignancy risk in LS at the population level. Clobetasol appeared to be protective against neoplastic transformation, particularly in early disease, while TCIs conferred no increased risk."

Dermatology • Gynecologic Cancers • Oncology • Squamous Cell Carcinoma • Vulvar Cancer

Combination therapies for vitiligo: a systematic review and network meta-analysis (AAD 2026) - "Simvastatin improved continuous outcomes (SMD 0.58; 0.02-1.15), but lost significance under a conservative correlation assumption (r=0.3). Gliadin-protected super oxide dismutase, methotrexate, silymarin, apremilast, pseudocatalase, alpha-lipoic acid, antioxidant cocktail, tacrolimus, pimecrolimus, and mometasone were not significant. These findings highlight baricitinib and piperine as promising candidates for future guideline integration and underscore the need for larger, high-quality RCTs to confirm their role in optimizing vitiligo treatment."

Combination therapy • Retrospective data • Review • Dermatology • Immunology • Vitiligo • CAT

Effectiveness of 308-nm Excimer Light with Pimecrolimus and Crisaborole in Pediatric Vitiligo: A Retrospective Study. (PubMed, Clin Cosmet Investig Dermatol) - "The combination of 308-nm excimer light therapy with topical pimecrolimus cream and crisaborole ointment demonstrates favorable efficacy in pediatric vitiligo, with only mild and well-tolerated adverse reactions. The integrated use of dermatoscopy, ImageJ software, Wood's lamp examination, and a color difference meter provides an objective, quantitative, and reproducible approach for digitally documenting changes in lesion color and area before and after vitiligo treatment."

Journal • Retrospective data • Dermatology • Immunology • Pediatrics • Vitiligo

Aquagenic Palmoplanta keratoderma: Response to Topical Pimecrolimus and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "The conventional therapy mainly involves topical application of aluminum chloride, followed by botulinum toxin injection, topical corticosteroids, topical salicylic acid, barrier agents, and oral antihistamines. This case report presents an APK patient who showed improvement after tw1o months of treatment with pimecrolimus cream, slight symptom recurrence following water exposure or sweating."

Journal • Dermatology

Line-field Confocal Optical Coherence Tomography Detects Subclinical Disease Activity in Atopic Dermatitis during Treatment with Pimecrolimus: An Intrapatient, Controlled Study. (PubMed, Acta Derm Venereol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparison chart: Topical nonsteroidal drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel. (PubMed, J Drugs Dermatol) - "Advanced topical nonsteroidal therapies represent an important evolution in AD management and are appropriate first-line options across disease severities, supporting sustained disease control and improved quality of life."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Exploring the therapeutic targets and molecular mechanisms of pimecrolimus in the treatment of oral lichen planus based on network pharmacology, machine learning, and molecular docking (PubMed, Zhonghua Kou Qiang Yi Xue Za Zhi) - "PPI and machine learning identified key targets including matrix metallopeptidase 2 (MMP2), mechanistic target of rapamycin (MTOR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). Molecular docking demonstrated that pimecrolimus had good binding activity with all the above targets, with binding energies all lower than -5 kcal/mol. This study systematically demonstrates that pimecrolimus may interfere with OLP progression by synergistically regulating key targets such as MMP2 (acting on erosive OLP), MTOR (acting on erosive OLP), and ERBB2 (acting on non-erosive OLP), and inhibiting the activity of inflammatory pathways including PI3K-Akt, TNF, and NF-κB."

Journal • Dermatology • Dermatopathology • Lichen Planus • Oncology • HER-2 • MMP2 • mTOR • TNFA • TYK2

CADPT17A12201: Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis (clinicaltrialsregister.eu) - P1/2 | N=104 | Recruiting | Sponsor: Novartis Pharma AG

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Different Patterns of Lichen Planus in Three Members of One Family. (PubMed, Case Rep Dermatol Med) - "Patients were treated with an individualized plan that included sunscreen use, potent topical corticosteroids, topical pimecrolimus, minoxidil, and systemic finasteride. To our knowledge, no other family in the literature has been reported to have such a wide range of LP variants. This series underscores the need for further research into genetic and environmental factors contributing to the development of LP and its variants."

Journal • Alopecia • Dermatology • Dermatopathology • Fibrosis • Immunology • Lichen Planus

Topical Tofacitinib for Atopic Dermatitis - Outcomes from Randomized Phase 3 Clinical Trial: First Approval. (PubMed, Indian J Dermatol) - "These comprise topical Ruxolitinib, oral Abrocitinib, and Upadacitinib...The present trial was conducted to evaluate the efficacy and safety of tofacitinib ointment 2% w/w (Tof-O) versus pimecrolimus cream 1% w/w (Pim-C) in adult patients with mild-to-moderate AD...https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=71771&EncHid=&userName=tofacitinib%20ointment. Interventional."

Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

PCLS-OMZ-3001: A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (clinicaltrials.gov) - P3 | N=477 | Terminated | Sponsor: Famy Life Sciences, a Viatris Company | Active, not recruiting ➔ Terminated; Sponsor Decision

Trial termination • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Combination of Oral Hydroxychloroquine and Topical Pimecrolimus 1% for Linear Morphea in Breastfeeding: A Rare Case with Favorable Outcome. (PubMed, Int J Womens Health) - "No adverse effects related to retinal toxicity were reported during the course of therapy. This case suggests that the combination of oral HCQ and topical pimecrolimus may represent a safe and effective therapeutic option for LM in breastfeeding women, although further evidence is needed to confirm long-term outcomes."

Journal • Immunology • Scleroderma • Systemic Sclerosis

Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs. (PubMed, Biomedicines) - " This study compared the in vitro potency of Thykamine™ against widely prescribed anti-inflammatory agents, including corticosteroids (betamethasone, clobetasol, hydrocortisone, prednisone) and non-steroidal therapies (crisaborole, pimecrolimus). These findings underscore the potential of Thykamine™ as a potent, multi-target anti-inflammatory therapy, which could offer substantial clinical advantages by effectively controlling chemokine-mediated inflammation with potentially fewer adverse effects. The results of this study support the need for evaluation of the clinical therapeutic efficacy of Thykamine™ in a wide range of autoimmune conditions."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis • CCL4

Innovative film-forming lyotropic crystal gel co-loaded with Pimecrolimus and Wrightia tinctoria oil for synergistic psoriasis therapy and patient acceptance. (PubMed, Int J Pharm) - "In vivo anti-psoriatic evaluation demonstrated marked lesion recovery, which was supported by histopathological observations and downregulation of inflammatory cytokines. Overall, the WTO-PMS co-loaded LLC-based film-forming gel presents a promising synergistic platform to overcome the solubility barrier of hydrophobic PMS and achieve effective topical management of psoriasis."

Journal • Dermatology • Immunology • Inflammation • Psoriasis

Calcineurin Inhibitors: Current Role, Toxicity Management, and Future Frontiers in Immunosuppression. (PubMed, Mol Neurobiol) - "Cyclosporine, tacrolimus, pimecrolimus and newer derivatives of cyclosporine such as voclosporin are calcineurin inhibitors (CNIs), have a potent immunosuppressant effect...This necessitates the need of continuous monitoring of drug concentrations and management of cardiovascular and metabolic risk factors. This narrative review summarizes the mechanism(s), the current clinical application(s), the safety concern(s), and the future direction(s) of the safer and targeted use of CNIs."

Adverse events • Journal • Review • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Transplantation • IL2 • NFATC1

Engineering of FK520 polyketide synthase for rapid access to quality control reference standards. (PubMed, Microb Cell Fact) - "The immunosuppressants FK506, FK520, and its chlorinated derivate pimecrolimus, are well known for accumulation of minor congeners in the fermentation, which demands costly and lengthy purification with industrial HPLC to obtain material of sufficient purity...It appears that the selectivity of the downstream AT4-containing module depends on the structural features of the incoming acyl chain; features installed by a module well upstream in the assembly line. Therefore, the global context of the PKS may be more impactful to the outcome of AT-engineering experiments than is generally considered."

Journal

The effects of Chinese botanical lotion and pimecrolimus cream in the treatment of chronic perianal eczema: a randomized clinical trial. (PubMed, Front Pharmacol) - "The combination of pimecrolimus cream and APL is more effective in the treatment of CPE than pimecrolimus cream alone, providing a promising new approach for the clinical management of perianal eczema. International Traditional Medicine Clinical Trial Registry, http://itmctr.ccebtcm.org.cn/en-US/Home/ProjectView?pid=58f1a168-bdf1-4e2a-a9bd-cf0f4a3ec06f as ITMCTR 2024000576."

Clinical • Journal • Atopic Dermatitis • Dermatology • Immunology • Pruritus

Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature review. (PubMed, Front Allergy) - "After oral compound glycyrrhizin, olopatadine hydrochloride, triprolidine hydrochloride, and topical pimecrolimus for a week, his facial lesions were completely cleared. No recurrence of similar rash or other adverse effects was observed during the subsequent follow-up period over 5 months. It is concluded that eczema could be induced temporarily by secukinumab, and maybe continued application."

Journal • Alopecia • Atopic Dermatitis • Dermatology • Immunology • Psoriasis • Pyoderma Gangrenosum • Sarcoidosis • IL17A

VULIS-3T: Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (clinicaltrials.gov) - P=N/A | N=45 | Not yet recruiting | Sponsor: Milosz Pietrus

New trial • Dermatology

Rebound New Atopic Dermatitis in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors (ACG 2025) - "All patients were treated with either topical steroids or pimecrolimus and an oral antihistamine for newly diagnosed AD... The mean age of the patients was 36.9 years (SD 9.2), with a median disease duration of 15 years (IQR 12-23). The median time from JAKi withdrawal to AD onset was 7 days (IQR 2-12). The rash was often described as pruritic and erythematous papules that were located on the face, anterior and posterior trunk, and upper extremities."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Rheumatology

Acquired Speckled Acrofacial Hypomelanosis: A Novel Case Report. (PubMed, Case Rep Dermatol) - "This case represents a novel presentation of acquired speckled acrofacial hypomelanosis with unique findings, including facial involvement and absence of hyperpigmentation. The patient's excellent response to pimecrolimus cream suggests this may be an effective treatment option for this rare condition."

Journal • Dermatology • Pediatrics

Upadacitinib Induced Facial Erythema and Edema in Atopic Dermatitis: A Paradoxical Adverse Event (EADV 2025) - "Materials & A 29-year-old female with long-standing moderate-to-severe AD was started on upadacitinib 15 mg/day following insufficient response and accessibility to prior treatments (topical agents, cyclosporine, phototherapy, baricitinib)...Upadacitinib was discontinued and pimecrolimus cream was initiated; subsequent clinical evaluation revealed partial regression of facial erythema following drug discontinuation... Facial dermatitis is a well-documented adverse event during dupilumab therapy, potentially linked to Malassezia hypersensitivity, rosacea, or allergic contact dermatitis. While JAK inhibitors are typically used to manage such cases, we report a rare paradoxical reaction where facial dermatitis was induced by JAK inhibition with upadacitinib. The exact mechanism remains unclear, but one plausible explanation involves the disinhibition of Th1 and Th17 pathways secondary to the suppression of Th2 cytokines such as IL-4 and IL-13."

Adverse events • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pruritus • Rosacea • IL13 • IL17A • IL22 • IL4 • JAK1

German AD-Best TREAT Registry (EADV 2025) - "The most commonly prescribed systemic therapy was Dupixent (n=77), followed by Lebrikizumab (n=26), Tralokinumab (n=22), Abrocitinib (n=13), Upadacitinib (n=10), Baricitinib (n=3), and others (n=2). In total, 66,86% (n=117) of patients received topical treatment, with 45,71% (n=80) treated with tacrolimus, 38,86% (n=68) with pimecrolimus, and 12,57% (n=22) with topical steroids. ADBest-TREAT provides an efficient platform for large-scale data collection, offering valuable insights into the real-world management of AD in Germany. With the anticipated inclusion of additional centers in the coming years, its capacity to generate comprehensive real-world evidence is expected to further expand."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus